Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angion Biomedica Corp.

www.angion.com

Latest From Angion Biomedica Corp.

Finance Watch: Q1 Biopharma Venture Capital Dips From All-Time High, But Numbers Still Impress

Private Company Edition: Biotech companies raised $3.9bn, down from $4.6bn in the first quarter of 2019 – a record-breaking year in the US – but dollars per deal stayed above $20m for a second year. Also, Fusion has April's second $100m-plus VC financing with a $105m Series B.

Financing StartUps and SMEs

Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene

About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.

Deals Asia Pacific

Pipeline Watch: Evolocumab, Roxadustat And SB-204, Top-line Results

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study

A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Angion Biomedica Corp.
  • Senior Management
  • Jay Venkatesan, MD, Pres. & CEO
    Itzhak D Goldberg, PhD, CSO
    Elisha Y Goldberg, Dir., Bus. Dev.
  • Contact Info
  • Angion Biomedica Corp.
    Phone: (516) 326-1200
    51 Charles Lindbergh Blvd.
    Uniondale, NY 11553
    USA
UsernamePublicRestriction

Register